MTOR and hereditary neuropathy with liability to pressure palsies: The therapeutic effect of the mTOR (mTORC1) inhibitor Rapamycin in a mouse model of HNPP suggests that mTOR signaling in Schwann cells must be considered a pharmacological target in human HNPP for which no therapy is available (Pisciotta et al, 2021).